[go: up one dir, main page]

WO2008079818A3 - Intravenous administration of water soluble analgesic formulations - Google Patents

Intravenous administration of water soluble analgesic formulations Download PDF

Info

Publication number
WO2008079818A3
WO2008079818A3 PCT/US2007/087943 US2007087943W WO2008079818A3 WO 2008079818 A3 WO2008079818 A3 WO 2008079818A3 US 2007087943 W US2007087943 W US 2007087943W WO 2008079818 A3 WO2008079818 A3 WO 2008079818A3
Authority
WO
WIPO (PCT)
Prior art keywords
intravenous administration
formulations
aspirin
water soluble
analgesics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/087943
Other languages
French (fr)
Other versions
WO2008079818A2 (en
Inventor
Robert E Martin
Arthur M Felix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLUPRIN PHARMACEUTICALS Inc
Original Assignee
SOLUPRIN PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLUPRIN PHARMACEUTICALS Inc filed Critical SOLUPRIN PHARMACEUTICALS Inc
Publication of WO2008079818A2 publication Critical patent/WO2008079818A2/en
Publication of WO2008079818A3 publication Critical patent/WO2008079818A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are formulations of analgesics suitable for intravenous administration, preferably to a human. Methods of formulating analgesics for intravenous administration, as well as methods of using the formulations of analgesics suitable for intravenous administration to treat various diseases or medical conditions are also provided. In preferred embodiments, the analgesic is aspirin. The formulations allow for the delivery of aspirin to patients in need of aspirin treatment in large doses and over extended periods of time without the gastrointestinal side effects that often accompany conventional aspirin therapy.
PCT/US2007/087943 2006-12-21 2007-12-18 Intravenous administration of water soluble analgesic formulations Ceased WO2008079818A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87659306P 2006-12-21 2006-12-21
US60/876,593 2006-12-21

Publications (2)

Publication Number Publication Date
WO2008079818A2 WO2008079818A2 (en) 2008-07-03
WO2008079818A3 true WO2008079818A3 (en) 2008-09-12

Family

ID=39563176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087943 Ceased WO2008079818A2 (en) 2006-12-21 2007-12-18 Intravenous administration of water soluble analgesic formulations

Country Status (2)

Country Link
TW (1) TW200841887A (en)
WO (1) WO2008079818A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2635269T1 (en) * 2010-11-04 2019-10-30 Aft Pharmaceuticals Ltd A combination composition
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123523A (en) * 1976-06-21 1978-10-31 Imperial Chemical Industries Limited Analgesic and sedative polypeptides
US5149320A (en) * 1988-04-11 1992-09-22 Dhaliwal Avtar S Composite anesthetic article and method of use
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20050175611A1 (en) * 2003-11-26 2005-08-11 Hanns-Christian Mahler Pharmaceutical preparation comprising an antibody against the EGF receptor
US20060205674A2 (en) * 2004-08-26 2006-09-14 Nicholas Piramal India Ltd. Prodrugs containing novel bio-cleavable linkers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123523A (en) * 1976-06-21 1978-10-31 Imperial Chemical Industries Limited Analgesic and sedative polypeptides
US5149320A (en) * 1988-04-11 1992-09-22 Dhaliwal Avtar S Composite anesthetic article and method of use
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20050175611A1 (en) * 2003-11-26 2005-08-11 Hanns-Christian Mahler Pharmaceutical preparation comprising an antibody against the EGF receptor
US20060205674A2 (en) * 2004-08-26 2006-09-14 Nicholas Piramal India Ltd. Prodrugs containing novel bio-cleavable linkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VUILLEMENOT ET AL.: "Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent-a pilot study in the setting of coronary angioplasty", THROMB. HAEMOST., vol. 81, no. 2, February 1999 (1999-02-01), pages 214 - 220, XP008002796 *

Also Published As

Publication number Publication date
WO2008079818A2 (en) 2008-07-03
TW200841887A (en) 2008-11-01

Similar Documents

Publication Publication Date Title
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
MX2009002196A (en) Buprenophine-wafer for drug substitution therapy.
MX2009009131A (en) Improvements in and relating to medicinal compositions.
NZ596041A (en) Use of guanethidine for treating hypertension by local vascular delivery
EP2392363A3 (en) Drug coated expandable devices
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
WO2007117509A3 (en) High delivery rates for lipid based drug formulations, and methods of treatment thereof
MY173215A (en) Acetylcysteine compositions and methods of use thereof
WO2004064734A3 (en) Combination therapies for the treatment of cancer
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
MX2009009132A (en) Improved medicinal compositions comprising buprenorphine and naltrexone.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2008067991A3 (en) Skin-friendly drug complexes for transdermal administration
WO2007095056A3 (en) Slow intraventricular delivery
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
MX2009009134A (en) Improved medicinal compositions comprising buprenorphine and nalmefene.
BRPI0510895A (en) 10-propargyl-10-deazaaminopterin pharmaceutical formulation for t-cell lymphoma treatment
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869442

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07869442

Country of ref document: EP

Kind code of ref document: A2